Other Events ·
On June 11, 2026, Definium Therapeutics, Inc. held its Annual General and Special Meeting of Shareholders
DFTXDefinium Therapeutics, Inc.
On June 11, 2026, Definium Therapeutics, Inc. held its Annual General and Special Meeting of Shareholders. Shareholders approved an amendment to the 2025 Equity Incentive Plan, increasing the number of common shares available for issuance by 5,000,000. Additionally, shareholders elected seven directors to serve until the 2027 annual meeting and appointed KPMG LLP as the independent registered public accounting firm. The company operates in the biotechnology industry, focusing on the development of therapeutics.